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Introduction
Menorrhagia is generally defined as excessive menstrual
bleeding in the absence of organic pathology, where
the blood loss in each menstrual cycle exceeds 80 mL
[1]. In the United Kingdom, 10% of women have had a
hysterectomy by the age of 43 years [2]. Of over 70,000
hysterectomies performed annually, more than half are
for menorrhagia. In up to 30% of these patients, the
uterus is found to be structurally normal and the diag-
nosis is dysfunctional uterine bleeding [3]. Hysterectomy
is a major operation with well-documented complica-
tions. Therefore, gynecologists have continued to explore
less radical methods for treating menorrhagia.
The treatment of menorrhagia in the 20th century
changed after 1960 with the introduction of hormonal
therapy, when a trial of cyclic therapy with estrogen and
progesterone became a therapeutic option. For those
intolerant of medical therapy and for whom fertility was
no longer desired, hysterectomy, however, had remained
the standard treatment for intractable menorrhagia.
More recently, a number of endometrial ablation tech-
niques have emerged. Goldrath et al [4] pioneered
endometrial laser ablation in 1981, with a study by
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SUMMARY
Objective: To evaluate the safety and efficacy of a microwave endometrial ablation (MEA) procedure to treat
patients with menorrhagia after endometrial curettage but without medical pretreatment.
Materials and Methods: From February to September 2001, 19 eligible and consenting premenopausal women
with menorrhagia underwent endometrial curettage, immediately followed by MEA. No medical pretreatment with
gonadotropin-releasing hormone (GnRH) analogues or danazol was given for endometrial preparation. The severity
of menorrhagia was assessed using the menstrual score. The patients were followed up for at least 3 years.
Results: Of the 19 women, 17 had completed at least 3 years’ follow-up. Fourteen patients (82%) were satisfied
with the posttreatment menstrual status, comparable with those patients receiving medical pretreatment of
other studies (78–94%). The mean menstrual score was 11.8 before treatment and 1.95, 2.25, 2.2, 2.1 and 2.1
at 3, 6, 12, 24 and 36 months posttreatment, respectively. Of the 12 patients who complained of dysmenorrhea
before surgery, six (50%) showed improvement. Three patients had hysterectomy; they all had adenomyosis and
dysmenorrhea which did not respond to medical analgesics.
Conclusion: MEA preceded by endometrial curettage instead of hormonal pretreatment had results comparable
to those of other studies in which the patients received hormones for 4–6 weeks before MEA. Endometrial
curettage is an alternative to drug pretreatment. [Taiwan J Obstet Gynecol 2007;46(2):152–156]
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Davis in Glasgow in 1985 confirming its efficacy [5].
Magos et al [6] introduced transcervical resection of the
endometrium (TCRE) in Britain in 1989. TCRE is effec-
tive, but it is a difficult technique to learn and carries
the risks of perforation and fluid overload.
To reduce the technical skill required to perform
endometrial ablation as well as its risks and costs, sev-
eral technologies of endometrial ablation have been
developed, including cryotherapy, direct circulation of
heated saline, laser interstitial therapy, radiofrequency
hyperthermia and microwave. Most of them need pre-
operative medical suppression of the endometrium.
Endometrial thickness varies from 3 to 11 mm dur-
ing the menstrual cycle. The aim of endometrial abla-
tion is to destroy the basal layer of the endometrium
and to prevent its regeneration. Microwave endometrial
ablation (MEA) was demonstrated by Sharp et al [7]
in 1995 to be a quick, safe and effective way to treat
menorrhagia. It produces necrosis to a depth of 5 to
6 mm [8]. Therefore, it is necessary to ensure that the
thickness of the endometrium is adequately reduced
prior to MEA in order to achieve destruction of the
basal layer. After endometrial sampling to exclude
malignancy, Sharp et al [7] pretreated all his patients
with one injection of goserelin acetate (Zoladex;
Zeneca, Cheshire, UK) 3.6 mg, 4 weeks before MEA or
danazol 800 mg daily for 4 weeks before the proce-
dure. We chose to use endometrial curettage rather
than hormonal pretreatment to reduce endometrial
thickness. MEA was then performed immediately after
curettage. We used this procedure in a series of
patients to compare its safety and efficacy with that
reported for MEA after hormonal pretreatment.
Materials and Methods
From February to September 2001, 19 eligible and
consenting premenopausal women with menorrhagia
underwent endometrial ablative surgery using equip-
ment producing microwaves at a frequency of 9.2 GHz
(Microsulis Plc, Waterlooville, Hampshire, UK). No hor-
mones were given prior to surgery. Under intravenous
general anesthesia with propofol, they were placed in
the lithotomy position. The cervix was dilated to 8 mm
and sharp endometrial curettage was performed. MEA
was done immediately after curettage. The operative
technique used was as described by Sharp et al in 1995
[7]. The patients were given ketoprofen (50 mg) for
postoperative pain relief and cephalexin (500 mg) for 3
days. No preoperative antibiotics or analgesics were
given. The severity of menorrhagia was assessed using the
menstrual score (Table) as described by Sharp et al in
1995 [7]. Patients were followed up for at least 3 years.
Questionnaires were completed at recruitment and at
3, 6, 12, 24 and 36 months of follow-up.
Results
Of the 19 women, 17 patients completed at least 36
months of follow-up. The other two patients reported
satisfaction at 3 months after the procedure but failed
to return for their appointment at 6 months.
A mean patient age of the 19 patients was 43.2 years
(range, 37–48 years), and the mean treatment time
required for MEA was 197 seconds (range, 125–390
seconds). The mean length of uterine cavity was 8.5 cm.
The mean menstrual score before treatment was 11.8
(range, 6–21), and it was 1.95, 2.25, 2.2, 2.1 and 2.1
at 3, 6, 12, 24 and 36 months, respectively. The satis-
faction rate was 89.5% (17/19) in the first 3-month
posttreatment follow-up. Two patients failed to return
for the next 3-month appointment. Of the 17 patients
followed up for at least 36 months, 14 (82%) were satis-
fied with the menstrual status after MEA. Two of the 19
(10.5%) were amenorrheic. Twelve patients complained
of dysmenorrhea before surgery, six (50%) of whom had
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Table. Menstrual score chart*
Score
Dysmenorrhea 2
Days of bleeding
7–10 1
> 10 2
Average length of cycle
If > 28 0
If 24–27 1
If < 24 2
Heavy days
For each 1
Sanitary protection
If double 2
Frequency of changing
If > 2 hourly 1
If > 1 hourly 2
Clots 1
Flooding 1
Housebound or time off work 2
Preoperation
Duration of problem > 5 yr 1
Postoperation
Any menstrual loss 1
*From Sharp et al [7].
improvement after MEA. This included the two women
with amenorrhea. Three cases had hysterectomy because
of dysmenorrhea and pathologic adenomyosis. No
malignancy was found in any of the endometrial tissue
samples.
Of the three dissatisfied patients, one had a decrease
in menstrual flow but an increase in duration. This
patient responded to hormone therapy. The second
patient had progressive adenomyosis and persistent
menorrhagia and dysmenorrhea. She underwent hys-
terectomy 7 months after MEA. The third patient had
improvement of menorrhagia for 6 months but had an
episode of massive vaginal bleeding requiring blood
transfusion. The bleeding did not respond to hormone
therapy or antifibrinolytic agents. Hysteroscopic eval-
uation disclosed an area of focal endometrial growth.
We then performed roller-ball endometrial ablation,
after which her bleeding stopped. She became amenor-
rheic after roller-ball ablation. There were two patients
who had adenomyosis and were satisfied with the post-
treatment hypomenorrhea status. But they cannot toler-
ate the dysmenorrhea and had hysterectomy at 3 years
postoperatively.
Discussion
In 1995, Sharp et al [7] demonstrated that MEA was 
a quick, safe and effective way to treat menorrhagia. In a
series of 23 patients, the average time needed for the
procedure was 2 minutes and 2 seconds, and 83% of the
patients were satisfied at 6 months after treatment. In
his subsequent experience with over 300 patients, there
were no intraoperative complications or uterine perfo-
ration. Only three patients were admitted for suspected
endometritis. In another study of 1,364 cases using
MEA, no emergency hysterectomies were necessary,
compared with 11 out of 1,000 cases using TCRE [9].
Only one serious complication occurred in one patient
(0.07%) who had had two previous cesarean sections
and developed a small bowel defect after MEA. Minor
complications included endometritis and blunt perfo-
rations by Hegar dilators (three cases) and applicators
(one case). Other reports of complications included one
case with small bowel perforation and one with pelvic
abscess [10,11]. Little complications were reported,
indicating that MEA is very safe when compared with
other hysteroscopic techniques.
Our study demonstrated that using diagnostic endo-
metrial curettage prior to MEA, rather than first giving
hormones as pretreatment, also provided adequate
thinning of the endometrium. It also provided endome-
trial tissue for pathologic analysis but did not require 
a separate procedure for that purpose. It was thus truly a
“one-stop” method. There were no complications in the
19 patients we treated in this way. Of the 17 available for
36 months’ follow-up, 82% (14/17) were satisfied with
the results, comparable with those of other studies
(78–94%) [8,9,12], as was the decrease in the menstrual
score from 12 before to 2 after MEA. Dysmenorrhea
improved in half of the patients who noted it prior to
MEA. We did have a lower incidence of post-MEA
amenorrhea (n = 2; 10.5%) than that reported by oth-
ers. There was one report which compared the effect of
MEA in the immediate postmenstrual phase without
hormone preparation and that after hormonal prepa-
ration. The amenorrhea rates were 52% and 62%,
respectively [13]. Our lower rate of amenorrhea may be
due to inadequate endometrial curettage, such that the
microwaves could not penetrate the basal layer in some
areas. The presence of intrauterine blood clots after
curettage may decrease the transmission of microwave
energy. Pretreatment with hormones has a global effect
on the endometrium, whereas curettage may miss some
areas, especially in the cornual area. Also, a large and
severely distorted uterine cavity is easy to be treated
incompletely [14]. Whether we will continue to see
such a low incidence of amenorrhea awaits assessment
of larger numbers of patients.
In the third patient who was dissatisfied because of
massive bleeding occurring 6 months after MEA, we
performed hysteroscopy to evaluate the uterine cavity.
There was normal endometrium still preserved in the
cornual area, which we thought was the cause of treat-
ment failure in this case. Sharp et al [7] also found that 
a significant number of patients had failure of MEA
because of trapped endometrium in the cornual area.
This low rate of amenorrhea may, in fact, be an
advantage in our population. Some Chinese women
wish to avoid amenorrhea. They think of it as sign 
of aging, even after the situation has been carefully
explained to them. Two patients returned, concerned
about hypomenorrhea. They were satisfied with the
resolution of their menorrhagia but were afraid that
they were prematurely entering menopause, despite
their hormone levels being normal. Amenorrhea cer-
tainly solves the problem of menorrhagia, but it may
create new anxiety for some patients.
Three patients had hysterectomy eventually. Only
one of them still had persisted heavy menstrual flow
and the other two were satisfied with the posttreatment
hypomenorrhea status. The most important reason for
them to have hysterectomy was dysmenorrhea due to
pathologic adenomyosis. The gross picture of the uterus
(Figure) after MEA showed a linear endometrium only.
The endometrium was destroyed by MEA 3 years before.
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Before the MEA procedure, 12 patients had dysmenor-
rhea. Six had improvement after MEA. The reasons for
the cure of dysmenorrhea may be that the microwave
energy penetrated the endometrium to the nearby myo-
metrium and destroyed the adenomyotic foci. So those
patients who had large adenomyosis and severe dys-
menorrhea should have had pretreatment consultation
about the outcomes of MEA management.
Endometrial preparation is recommended in all
ablation technologies except the NovaSure system [15].
Treatment with a GnRH analogue or danazol prior to
hysteroscopic surgery has the following advantages:
improved hysteroscopic view, reduced blood loss,
absorption of fluid distending the uterus, and higher
postoperative amenorrhea rates [16]. However, the cost
of the medication is high, and at least 4 weeks of treat-
ment are needed to achieve endometrial suppression.
Mechanical preparation of the endometrium, therefore,
seems to be a good alternative to medical preparation.
Both Nd:YAG laser and thermal balloon technologies
have been used successfully with results comparable to
that using traditional medical preparation [17,18]. Endo-
metrial curettage just prior to MEA thus saves time
and money, as well as provides for detection of malig-
nancy and enhancing patient compliance. Timing of the
procedure is not dependent on the menstrual cycle.
MEA is simple to learn and perform. This was our
first experience with the technique, which may explain
why our average treatment time of 195 seconds was
longer than that reported by others. The first five
patients required an average of 297 seconds, when our
learning curve was steep. Initially, we used ultrasound
to confirm the position of the applicator, and we also
used hysteroscopy to evaluate the effects of MEA in
the first four patients. Visual inspection in these
patients revealed destruction of the endometrium
without perforation.
The reported incidence of complications with MEA
has been very low. We had no major complications
resulting from the procedure. Five patients, who com-
plained of mild lower abdominal pain for 1 to 2 days,
responded incompletely to NSAIDs (ketoprofen, 50 mg
q 6 h), but it was tolerable. There were no cases of endo-
metritis. All the patients had mild vaginal discharge
lasting for about 2 to 3 weeks.
The results of this initial series are encouraging. 
We believe that substituting endometrial curettage for
hormonal treatment is a reasonable alternative to
achieving thinning of the endometrium prior to MEA,
without compromising the results.
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